Progress report

Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease

The current interest in hepatic osteodystrophy was stimulated by the discovery in 1969 that vitamin D undergoes 25-hydroxylation in the liver.\(^1\) It has subsequently been shown that the metabolite thus formed, 25-hydroxyvitamin D (25OHD) is the major circulating metabolite of vitamin D; the major active metabolite, 1,25-dihydroxyvitamin D\(_3\) is formed by 1\(\alpha\)-hydroxylation of 25OHD, this step occurring almost exclusively in the kidney.\(^2\) Although diet was formerly believed to be the major source of vitamin D in man it has been shown, both in the UK and North America, that endogenous skin synthesis is quantitatively the most important source,\(^3\)\(^4\) cholecalciferol (vitamin D\(_3\)) being produced from the precursor 7-dehydrocholesterol in the presence of ultraviolet irradiation.\(^5\)

After the demonstration that 25-hydroxylation occurred in the liver many groups, both in Europe and North America reported low serum or plasma 25OHD concentrations in patients with chronic cholestatic, alcoholic and other forms of liver disease.\(^6\)\(^{22}\) The pathogenesis of this vitamin D deficiency aroused considerable controversy. Whilst impaired hepatic metabolism of vitamin D was an obvious possibility, other causes such as reduced exposure to ultraviolet irradiation, low dietary vitamin D intake, impaired cutaneous synthesis of vitamin D\(_3\) caused by jaundice and malabsorption of vitamin D also required investigation.

Hepatic production of vitamin D

Hepatic production of vitamin D in man has been studied mainly by measurement of the serum 25OHD response to vitamin D administration, using either unlabelled or radioactive vitamin D. The former studies have often involved administration of pharmacological doses of vitamin D and the results obtained may thus not be of physiological significance although they are relevant when considered in the light of vitamin D therapy. Radiolabelled vitamin D studies, in most of which the vitamin is injected as an intravenous bolus, have also to be interpreted with some caution as both the rate of delivery of the vitamin to the circulation and the form in which it is delivered are unphysiological. The appearance of 25OHD in plasma after vitamin D administration reflects hepatic uptake and hydroxylation of the vitamin together with hepatic release and metabolism of the metabolite, so that these investigations do not directly measure 25-hydroxylation of 25OHD. In addition, changes in serum 25OHD levels after oral vitamin D will be affected by absorption of the vitamin from the intestine.

Early evidence for impaired hepatic production of 25OHD in liver
disease was reported by Hepner et al.,23 who showed an impaired serum 25OHD response to parenteral vitamin D in 27 patients with alcoholic cirrhosis; however, in three patients with primary biliary cirrhosis, a normal response was seen. Wagonfeld et al7 found no significant rise in serum 25OHD levels after large doses of oral or subcutaneous vitamin D in patients with primary biliary cirrhosis; however, these results could also be explained on the basis of poor intestinal absorption and low bioavailability respectively of the vitamin. In contrast, Skinner et al.24 showed that if provided with sufficient vitamin D, patients with severe chronic cholestatic liver disease could achieve normal serum 25OHD levels; this is confirmed by the finding by several other groups of normal serum 25OHD levels in vitamin D-treated patients with liver disease.13 17 21 In Skinner’s study there was, however, some impairment of the serum 25OHD response to a single injection of vitamin D2. Most subsequent studies have shown normal hepatic production of 25OHD in chronic cholestatic liver disease,25 26 15 particularly when the results are interpreted in the light of the prevailing vitamin D status27; two studies have also demonstrated a normal plasma half-life of radiolabelled vitamin D3 and 25OHD3.26 15 In contrast, the data in alcoholics are conflicting, evidence for23 28 and against29–32 impairment of hepatic 25OHD production being reported. One study also showed a reduced plasma half-life of radiolabelled vitamin D3,28 possibly reflecting increased hepatic uptake of the vitamin.

Intestinal absorption of vitamin D

Vitamin D absorption is bile acid dependent33 and thus should be reduced in chronic cholestatic liver disease. The first report of vitamin D malabsorption by Thompson et al.34 in two patients with biliary steatorrhoea has subsequently been confirmed by Krawitt et al.25 and Barragry et al.31 in patients with primary biliary cirrhosis. 25OHD is also present in the diet and there is some indirect evidence for malabsorption of this metabolite in primary biliary cirrhosis.9 35 Therapy with the bile acid binding agent, cholestyramine, may further decrease absorption of vitamin D and 25OHD.9 36–38 The data in alcoholic liver disease are conflicting, some studies reporting impaired vitamin D absorption29 32 but another claiming no such abnormality.31

Urinary excretion of vitamin D metabolites

Evidence for increased urinary excretion of polar vitamin D metabolites in primary biliary cirrhosis has been reported,15 25 the amount of metabolite excreted being correlated with serum bilirubin levels. It is unclear whether increased urinary excretion represents an alternative excretory pathway to bile39 in patients with cholestasis, altered vitamin D metabolism or reduced renal tubular reabsorption of the vitamin D metabolites. Although increased urinary loss may contribute to vitamin D deficiency in chronic cholestatic liver disease, it is unlikely to be quantitatively important in most cases.

Vitamin D binding protein

Both vitamin D and 25OHD are transported in human plasma bound to a
specific protein. DBP or group-specific component protein (Gc-globulin), an \(\alpha_2\) globulin. \(^{40}\) Reduced serum DBP levels have been reported in patients with liver disease \(^{28}\) \(^{41}-^{44}\); however, because the saturation of the binding protein is normally very low (2-3\%) the reduction in serum DBP levels encountered in chronic liver disease is insufficient to affect the serum \(25\text{OHD}\) concentration.

**Dietary intake of vitamin D**

There are little data available on dietary vitamin D intake in patients with chronic liver disease, both low \(^{15}\) \(^{21}\) and normal \(^{28}\) intakes being reported in small numbers of patients. Alcoholics may well have low intakes as part of their poor diet and patients with fat malabsorption may avoid dairy products and oily foods such as tinned fish, thus ingesting only small amounts of vitamin D.

**Endogenous synthesis of vitamin D**

Relatively little is known about the effects of jaundice on cutaneous vitamin D\(_3\) synthesis. A normal serum \(25\text{OHD}\) response to ultraviolet radiation in jaundiced patients has been reported, \(^{15}\) \(^{21}\) and Long et al\(^{45}\) found no impairment of cutaneous synthesis of vitamin D\(_3\) in rats with hyperbilirubinaemia when compared with anicteric controls. Thus the available data indicate that there is no significant impairment of cutaneous vitamin D\(_3\) synthesis in jaundiced patients.

**Other vitamin D metabolites**

Normal production of radiolabelled \(1,25(\text{OH})_2\text{D}_3\) and \(24,25\)-dihydroxy-vitamin D\(_3\) (24, \(25(\text{OH})_2\text{D}_3\)) from the radiolabelled precursor vitamin has been reported in primary biliary cirrhosis \(^{27}\) and normal plasma \(1,25(\text{OH})_2\text{D}_3\) levels have also been documented in vitamin D replete patients. \(^{46}\) \(^{47}\) In addition, low serum \(1,25(\text{OH})_2\text{D}_3\) levels in vitamin D depleted patients with primary biliary cirrhosis can be restored to normal with small doses of vitamin D. \(^{21}\) The situations with regard to plasma concentrations of \(24,25(\text{OH})_2\text{D}_3\) is less clear, Kaplan et al\(^{46}\) reporting low levels in patients with primary biliary cirrhosis despite normal plasma \(25\text{OHD}\) concentrations, but Davies et al\(^{41}\) demonstrating restoration of normal levels in vitamin D depleted primary biliary cirrhosis patients given small oral doses of vitamin D and Cuthbert et al\(^{47}\) reporting normal or near normal levels in vitamin D replete patients.

**Metabolic bone disease**

Two major types of metabolic bone disease have been described in association with liver disease, namely osteoporosis and osteomalacia. The definition of these metabolic bone diseases is central to the issue of hepatic osteodystrophy and will now be discussed in more detail.

**Osteoporosis**

Osteoporosis is a heterogeneous skeletal disorder characterised by bone loss, \(^{48}\) which may result in fracture, particularly of the vertebrae, hip, and
Clinical and radiological changes appear only when bone loss is advanced and possibly irreversible. Plasma and urine biochemistry are characteristically normal in osteoporosis although the plasma alkaline phosphatase may be raised after fractures. Because the distribution of osteoporosis is heterogeneous and loss of bone mineral in cortical and trabecular bone differs with respect both to onset and rate, early diagnosis requires measurement of bone mineral content at selected sites of clinical interest, particularly vertebral trabecular bone and both cortical and trabecular bone in the femoral neck. There are now three techniques available which provide accurate and reproducible measurements of bone mineral content in both axial and appendicular skeleton; quantitative computerised tomography, dual photon absorptiometry and neutron activation analysis. Quantitative computerised tomography is particularly well suited for measurements in vertebral trabecular bone, although it can also be used at other skeletal sites. Dual photon absorptiometry can also measure bone mineral content in appendicular or axial skeleton but unlike quantitative computerised tomography is unable to select out trabecular bone in the spine, where it measures combined cortical and trabecular bone mineral content together with any extravertebral mineral present in the area of measurement. The method is most commonly applied to the lumbar spine and femoral neck. Neutron activation analysis can measure either total or partial body calcium; partial body neutron activation analysis can be applied to a number of skeletal sites including the spine, hand, and forearm.

The advent of these techniques over the past few years invites reconsideration of the definition of osteoporosis. Its definition as a condition in which fracture has occurred will exclude many patients with abnormally low bone mineral content who may develop osteoporotic fractures in the future and who are most likely to benefit from treatment. Providing that adequate control data are available, osteoporosis is better defined as a condition in which bone mineral content at clinically relevant skeletal sites is greater than 2 standard deviations below the control mean value, matched for age, sex and, where relevant, number of years after menopause.

From the above discussion it is clear that if a diagnosis of osteoporosis is based on vertebral fractures or loss of vertebral height the true prevalence of pathological bone loss will be underestimated. In addition, trabecular bone volume measurements in iliac crest biopsies are not necessarily representative of the clinically relevant sites; indeed, the iliac crest trabecular bone volume may be normal in patients with osteoporotic fracture. Studies utilising metacarpal morphometry or single photon absorptiometry of the radius have provided valuable data on cortical bone loss but this information cannot be freely extrapolated to other skeletal sites, least of all vertebral trabecular bone.

**OSTEOMALACIA**

Osteomalacia is characterised by defective mineralisation of bone and is essentially a histological diagnosis. The commonest symptom is bone pain; in more advanced cases, bone tenderness, proximal muscle weakness and fracture may occur. The classical biochemical changes of hypocalcaemia, hypophosphataemia and raised plasma alkaline phosphatase are not
uniformly reliable indicators of bone disease and symptomatic, histologically proven osteomalacia has been documented in patients with normal plasma biochemistry.\textsuperscript{55, 56} Plasma alkaline phosphatase is the most accurate indicator of bone disease in patients with normal liver function\textsuperscript{57} but is obviously of much less value in patients with liver disease unless the contribution to total enzyme activity made by bone and liver isoenzymes can be accurately assessed. The radiological changes of pseudo-fracture and pathological fractures generally occur late in osteomalacia and may be absent even in severe cases. Examination of bone histology provides the only accurate method of diagnosis; as the histological changes of osteomalacia are distributed throughout the skeleton, biopsy at a single site is representative and in practice the iliac crest is chosen.

Histologically, osteomalacia is associated with an increase in the amount of osteoid or unmineralised bone but this may also be seen in a variety of other metabolic bone disorders. The cardinal feature of osteomalacia is defective mineralisation and proper documentation of this requires the use of double tetracycline labelling.\textsuperscript{58} Tetracyclines are taken up at the mineralisation front in bone and can be visualised by fluorescence microscopy. The use of a double, time-spaced tetracycline label, given orally to the patient before the biopsy, allows examination both of the linear extent of mineralisation and its rate, from which in turn, bone formation rates at tissue and cellular level can be calculated.\textsuperscript{59} Rigorous diagnostic criteria for osteomalacia, which should be used in prevalence studies, are as follows: (1) increased osteoid seam width; (2) prolonged osteoid maturation period (calculated from osteoid seam width and bone formation rate at cellular level), and (3) reduced mineralisation rate.\textsuperscript{60} In the absence of tetracycline labelling, an increase in osteoid amount together with reduced calcification fronts, as demonstrated by stains such as toluidine blue,\textsuperscript{61} comprise the absolute minimum criteria. As in the case of osteoporosis, control data are of prime importance and should ideally be derived from the same geographical area as the patient population. Unlike the techniques available for measuring bone mineral content, bone histomorphometry is associated with a considerable total measurement variance\textsuperscript{62-64} and small differences between control and patient populations, especially where control data from other laboratories are used, may be because of methodological or systematic interobserver differences rather than reflecting true differences between the two groups.

**OSTEOMALACIA IN CHRONIC LIVER DISEASE**

Estimates of the prevalence of osteomalacia in chronic cholestatic liver disease range between 0 and 72%.\textsuperscript{13, 15, 17, 20, 47, 65-72} This enormous variation reflects several factors. First, few of the reported studies have been unselected, secondly, the severity of liver disease in the patients studied has varied, and thirdly, histological criteria for the diagnosis of osteomalacia have differed. Although reports of osteomalacia associated with chronic liver disease have appeared in the literature for many years,\textsuperscript{73-76} histological confirmation had to await techniques for cutting undecalcified sections of bone\textsuperscript{77} and for demonstrating calcification fronts in bone.\textsuperscript{58, 61} Atkinson \textit{et al.}\textsuperscript{65} examined bone histology qualitatively in 25 patients with chronic liver disease, mainly cholestatic, and concluded that there was evidence of osteomalacia in nine; however, techniques for
examining calcification fronts were not available at that time and inspection of the data in the light of present day knowledge suggests that osteomalacia was probably only present in four patients. Quantitative histology in 11 jaundiced patients with chronic liver disease was reported by Paterson and Losowsky,66 who found no osteomalacia on the basis of osteoid measurements. The first study in which both osteoid amount and calcification fronts were quantitatively assessed reported osteomalacia in four of 11 selected patients with primary biliary cirrhosis.9 Thus it was definitely established that osteomalacia occurred in patients with chronic cholestatic liver disease; however, the prevalence of this bone disease was less clear.

The study of Long et al13 in 1978 indicated a surprisingly high prevalence of osteomalacia in association with chronic liver disease, 22 of 32 patients studied being classified as osteomalacic in spite of long term high dose parenteral vitamin D prophylaxis in 50%. Decalcified sections only were examined, however, and thus bone mineralisation could not be assessed. Moreover, the upper limit of normal for absolute osteoid volume of 0·5% used in their study is not supported by published control data; if an abnormally high value is defined as >2 standard deviations above the control mean value, matched for age and sex, then values of up to 2% would be regarded as normal.64 Using these criteria, only six (18·8%) patients would have excess osteoid. Results from a subsequent study of a similar patient population supported the contention that the prevalence of osteomalacia had been overestimated; quantitative assessment of both osteoid amount and calcification fronts revealed osteomalacia in only four of 32 unselected patients (12·5%), mild in two.17 Since then, a number of unselected studies both in Europe and North America have confirmed a low or absent prevalence of osteomalacia in chronic liver disease. Recker et al71 reported no osteomalacia in 27 American patients with primary biliary cirrhosis and seven with alcoholic cirrhosis and Herlong et al,69 Matloff et al,70 and Cuthbert et al47 have all reported similar findings in smaller groups of American patients with primary biliary cirrhosis; in these studies a full histomorphometric evaluation was carried out. In the largest study to date, using the full diagnostic criteria referred to earlier, Stellon et al72 were unable to find a single case of osteomalacia in 36 British patients with chronic cholestatic liver disease.

Rickets in Infants and Children with Cholestatic Liver Disease
Rickets has been reported in a high proportion of infants and children with hepatobiliary disease. Kobayashi et al reported radiological evidence of rickets in 59% of 21 with neonatal hepatitis and two of four with intrahepatic cholestasis.78 The main pathogenetic factor is thought to be malabsorption of dietary vitamin D,16 79 the major source of the vitamin in infants; however, evidence for reduced hepatic production of 25OHD has been reported in one patient with neonatal hepatitis.16

Parenteral vitamin D,78 79 oral 25OHD₃,80 and parenteral 1,25(OH)₂D₃,81 have all been shown to be effective in healing rickets associated with cholestasis, whereas even high doses of oral vitamin D appear ineffective. Because neither 25OHD₃ nor parenteral 1,25(OH)₂D₃ has a product licence in the UK, treatment with parenteral vitamin D is recommended, daily doses of 3000 IU apparently being effective.79
PATHOGENESIS OF OSTEOMALACIA ASSOCIATED WITH CHRONIC LIVER DISEASE

The central role of vitamin D deficiency in the pathogenesis of osteomalacia associated with chronic liver disease is shown, first, by the presence of low serum 25OHD levels in osteomalacic patients, and secondly, by the therapeutic response to vitamin D. Further indirect evidence for the pathogenetic role of vitamin D deficiency comes from the demonstration of secondary hyperparathyroidism in some osteomalacic patients, as evidenced by raised serum parathyroid hormone levels, decreased tubular phosphate reabsorption, increased urinary cyclic AMP excretion, and histological evidence of osteitis fibrosa. It is important to note, however, that low serum 25OHD levels are also well documented in patients with no histological evidence of osteomalacia. Whether this reflects insufficient duration of vitamin D deficiency for the development of osteomalacia or the need for additional pathogenetic factors is unknown.

Calcium malabsorption has been reported in both parenchymatous and biliary liver disease. There is evidence that this is at least partly caused by vitamin D deficiency; thus some improvement has been reported after parenteral vitamin D, oral 25OHD, and oral 1,25(OH)2D. Precipitation of calcium salts by unabsorbed fats within the intestinal lumen may also contribute to calcium malabsorption. Finally, malabsorption of phosphate has been reported in chronic liver disease, with some improvement after oral 1,25(OH)2D or oral 25OHD administration.

TREATMENT OF HEPATIC OSTEOMALACIA

Both oral and parenteral administration of either vitamin D or its metabolites have been shown to be effective in healing osteomalacia associated with chronic cholestatic liver disease. Weekly injections of 100 000 IU of vitamin D2 were shown to resolve the histological abnormalities of osteomalacia in two patients with primary biliary cirrhosis within six and 13 months respectively; oral 25OHD3, in daily doses of 50 or 100–200 µg, parenteral 1,25(OH)2D3 15 µg/month and oral 1α-hydroxyvitamin D3, 2 µg/day, have also been shown to heal hepatic osteomalacia. All these studies have focused on patients with chronic cholestatic liver disease; there are no corresponding data in alcoholic liver disease.

Experiments in animals indicated some vitamin D resistance in hepatic osteomalacia and large doses have traditionally been recommended for its treatment in man. If the main pathogenetic factors are privational, however, small doses should be sufficient. In addition, the parent vitamin itself should be effective as hepatic metabolism of vitamin D is relatively well preserved even in severe liver disease. Davies et al have shown that small amounts of oral vitamin D do indeed heal hepatic osteomalacia, doses of between 400 and 4000 IU being used, according to the degree of vitamin D malabsorption present.

OSTEOPOROSIS IN CHRONIC CHELASTIC LIVER DISEASE

TRABECULAR OSTEOPOROSIS

Case reports of spinal osteoporosis associated with chronic cholestatic liver
disease date back to early this century.\textsuperscript{93-96} Ahrens \textit{et al}\textsuperscript{7} described severe back pain, vertebral crush fractures and kyphosis in seven of 22 patients with chronic cholestatic liver disease, a further five patients having radiological evidence of skeletal demineralisation. A high prevalence of spinal osteoporosis was also reported by Atkinson \textit{et al},\textsuperscript{65} 10 out of 25 patients showing radiological signs of osteoporosis. Subsequent studies, usually involving selected patients, have produced similar findings. Thus Kehayoglou \textit{et al}\textsuperscript{67} found radiological signs of demineralisation in 10 of 12 patients and Compston \textit{et al}\textsuperscript{17} in 14 of 32. Long \textit{et al}\textsuperscript{13} reported osteoporosis in 40\% of 22 patients with chronic cholestatic liver disease; however, the diagnosis was based on a trabecular bone volume in iliac crest biopsies of <20\%, a figure which is generally regarded as too high. Using the more acceptable criterion of an iliac crest trabecular bone volume >2 standard deviations below the normal age and sex-matched mean value, varying prevalence rates of between 9\% and 60\% have been reported,\textsuperscript{47,69,70-72} two unselected studies reporting figures of 9\% (1/11)\textsuperscript{47} and 17\% (6/36)\textsuperscript{72}; in the latter study, when both a subnormal iliac crest trabecular bone volume and vertebral fractures were used as criteria for osteoporosis, the prevalence rate rose to 36\%.

\textbf{CORTICAL OSTEOPOROSIS}

The first quantitative study of cortical osteoporosis in chronic liver disease was reported by Paterson and Losowsky,\textsuperscript{66} who carried out metacarpal thickness measurements in 38 patients with a variety of liver diseases. The majority of values were below the mean normal thickness although only three were >2 standard deviations below this value. Subsequent reports have confirmed an increased prevalence of cortical osteoporosis in chronic cholestatic liver disease, using measurements of metacarpal thickness and/or single photon absorptiometry of the radius.\textsuperscript{7,69,70,72,98-100} In a study of 83 women with primary biliary cirrhosis, comparison of patients with age and sex matched controls revealed significantly increased medullary width together with a decreased combined cortical thickness and \% cortical area, indicating increased endosteal resorption of the cortex.\textsuperscript{98} Stellon \textit{et al}\textsuperscript{100} using metacarpal morphometry, single photon absorptiometry of the radius and measurements of mean cortical thickness in iliac crest biopsies, found evidence of cortical osteoporosis in 28\% of 36 unselected patients with chronic cholestatic liver disease, a figure similar to that reported by Epstein \textit{et al},\textsuperscript{99} using metacarpal morphometry alone.

\textbf{OSTEOPOROSIS IN OTHER FORMS OF CHRONIC LIVER DISEASE}

Cortical and/or spinal osteoporosis have been reported in association with alcoholic liver disease,\textsuperscript{11} 13,101-108 chronic active hepatitis,\textsuperscript{66} 99 109 cryptogenic cirrhosis,\textsuperscript{98} idiopathic haemochromatosis,\textsuperscript{110,111} glycogen storage disease\textsuperscript{112} and primary benign hepatoma.\textsuperscript{112} Increased bone loss in alcoholics is well documented\textsuperscript{113,114}; the risk of fractures, including osteoporotic vertebral fractures, is also increased.\textsuperscript{115,116} One study suggests that the mechanism of bone loss in alcohol induced osteoporosis may be defective osteoclastic function.\textsuperscript{117}

The pathogenesis of osteoporosis associated with alcoholism is poorly understood and the relationship between bone loss and hepatic dysfunction rather than alcohol \textit{per se} far from clear. Factors such as malnutrition with
low calcium and protein intake, vitamin D deficiency, calcium malabsorption, lack of physical activity, altered sex hormone status and heavy tobacco consumption may all play a role. In addition, the higher risk of trauma in alcoholics clearly contributes to the increased fracture incidence.

Stellon et al have recently studied the prevalence of osteoporosis in 36 unselected patients with chronic active hepatitis, maintained on corticosteroids, using measurements of trabecular bone volume and cortical thickness in iliac crest biopsies together with metacarpal morphometry and single photon absorptiometry of the radius. Forty seven per cent were found to have cortical and/or trabecular osteoporosis, bone loss in the iliac crest showing a weak inverse correlation with the total dose of steroids; in contrast the presence of cirrhosis was not related to the degree of bone loss at any of the sites studied.

TREATMENT OF OSTEOPOROSIS IN CHRONIC LIVER DISEASE
Very little is known about the treatment of hepatic osteoporosis. Oestrogens, which are effective in preventing postmenopausal bone loss, are generally regarded as contraindicated in chronic cholestatic liver disease, as are anabolic steroids. Fluoride therapy, effective in some patients with postmenopausal or senile osteoporosis, is not specifically contraindicated in liver disease, but no trials of its use in hepatic osteoporosis have been reported.

The small amount of data available relate to the use of calcium and vitamin D therapy. Evidence for, and against a protective effect of vitamin D or its metabolites on bone loss in chronic liver disease has been claimed, these studies being based on measurements of trabecular bone volume in iliac crest biopsies and/or bone mineral content in the radius. The length of the treatment period before reassessment, however, has been too short in all these studies for accurate determination of the long term effects of treatment on bone mass and no study has examined the effects of such treatment on spinal trabecular bone mineral content. The use of calcium supplements has also been advocated in hepatic osteoporosis; calcium infusions were reported to produce subjective relief of bone pain in 14 patients with primary biliary cirrhosis and Epstein et al produced more objective evidence with the demonstration that metacarpal cortical bone loss in women with primary biliary cirrhosis could be prevented with either calcium gluconate or hydroxyapatite.

PATHOPHYSIOLOGY OF OSTEOPOROSIS ASSOCIATED WITH CHRONIC LIVER DISEASE
Osteoporosis may result from either a high or low turnover state. In the former, bone formation is normal or increased, but is exceeded by resorption, whereas in low turnover osteoporosis, bone formation is reduced. This classification bears important therapeutic implications, as therapy would be aimed primarily at reducing resorption in high turnover disease, but at stimulating bone formation in low turnover states.

Reduced osteoid volume and surface extent have been shown in several studies of patients with chronic cholestatic liver disease and, where reported, the mean osteoid seam width has also been reduced. Osteoid seam width depends on three factors; first, the rate of matrix
synthesis, secondly, the osteoid maturation period and thirdly the mineral appositional rate. In the presence of the prolonged osteoid maturation period and normal or low mineral appositional rate demonstrated in chronic cholestatic liver disease, reduced osteoid seam width indicates grossly reduced matrix synthesis. In support of this concept, there is increasing evidence that the rate of bone formation is reduced in chronic cholestatic liver disease, both at the cellular level and, to a greater extent at tissue level. Cuthbert et al calculated bone formation rate at tissue level; comparison with control data from other sources reveals low formation rates in three patients and low-normal rates in the remaining four. In addition, the percentage of osteoid taking up a double label, expressed in this study as a percentage of osteoid surface, was considerably reduced. Mean values reported by Herlong et al for mineral appositional rate and bone formation rate at tissue level were at the lower end of the normal range. Finally, Stellon et al have reported low bone formation rates at cellular and tissue level in 30 patients with primary biliary cirrhosis, using age and sex-matched control data for comparison. In this study, the mean wall thickness, or the thickness of the completed bone remodelling unit, was also shown to be reduced in the patient group, a further indication of impaired bone formation. As sigma, the bone formation period, was normal or increased, impaired function of osteoblasts rather than a reduction in their life span is likely to be responsible.

The evidence regarding bone resorption in chronic cholestatic liver disease is more conflicting. Two studies have shown a modest increase in the surface extent of resorption; this does not necessarily imply an increase in resorption rate but might simply reflect impaired bone formation at the resorption sites, as formation always follows resorption in the normal sequence of bone remodelling. The observation in both studies that despite increased surface extent of resorption cavities, osteoclasts were sparse, would favour this explanation. In addition, biochemical indicators of increased resorption such as raised serum immunoreactive parathyroid hormone levels and increased urinary hydroxyproline and calcium excretion have been absent in the majority of patients studied. The demonstration by Cuthbert et al, however, that resorption surfaces and serum immunoreactive parathyroid hormone levels fell after six months of vitamin D therapy would support the opposite view, namely that active bone resorption is increased.

The Figure illustrates the postulated chain of events in osteoporosis associated with chronic cholestatic liver disease. Osteoblasts are believed to be responsible for matrix synthesis, maturation and mineralisation. It is suggested that their function is selectively impaired so that matrix synthesis is affected to a much greater extent than maturation or mineralisation. Decreased bone formation results in reduced mean wall and trabecular plate thickness and hence to a reduced trabecular bone volume. The possible role of increased bone resorption requires further investigation; studies using recently described methods to measure resorption cavity depths should help to resolve this issue. Because the trabecular plate density remains normal, however, erosion of whole trabecular plates does not appear to contribute to bone loss.

A recent study of bone histomorphometry in alcoholic liver disease describes rather different findings. In contrast with chronic cholestatic liver...
Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease

Impaired osteoblast function

↓ or Normal mineral appositional rate

↑ Osteoid maturation period

↓ Matrix synthesis +++

↓ Osteoid seam width

↓ Osteoid surface

↓ Bone formation rate at cellular and tissue level

↓ Mean wall thickness

↓ Mean trabecular plate thickness

↓ Trabecular bone volume

Figure Proposed pathophysiology of osteoporosis associated with chronic cholestatic liver disease.

disease, resorption surfaces were significantly reduced whilst osteoid seam width, mineral appositional rate and osteoid maturation period were normal. Bone formation rate and mean wall thickness were, however, reduced as in chronic cholestatic liver disease. The authors conclude that alcoholic liver disease is associated with low bone turnover and suggest that whilst the efficiency of osteoblasts is normal, as evidenced by the normal mineral appositional rate, there is a reduction in their life span resulting in reduced mean wall thickness. Measurement of the bone formation period, \( \sigma_f \), would be required to confirm this theory. This report raises the interesting possibility that the pathophysiology of bone disease in alcoholic liver disease may differ from that seen in chronic cholestatic liver disease.

Conclusions

Privational factors are probably mainly responsible for the increased prevalence of vitamin D deficiency in patients with chronic liver disease. Although malabsorption of dietary vitamin D and 25OHD has also been shown, this is unlikely to be an important pathogenetic factor except in those patients with reduced endogenous synthesis of the vitamin. Other factors such as increased urinary losses of vitamin D and cholestyramine therapy may contribute to vitamin D deficiency in chronic cholestatic liver disease. There is little evidence for any significant impairment of hepatic
25OHD production in chronic cholestatic liver disease; in alcoholic liver disease, the evidence is more conflicting. Most evidence supports the view that formation of the dihydroxyated metabolites, 1,25 and 24,25(OH)2D3 is normal.

In the past, controversy over the prevalence of osteomalacia in chronic liver disease has arisen largely because of the use of inadequate histological criteria for its diagnosis and, in particular, failure to assess bone mineralisation. Early reports of a high prevalence have been disproved by subsequent studies in which more rigorous criteria have been used. There is no doubt that osteomalacia does occur in association with chronic liver disease, but its prevalence is low. Virtually all reported cases come from the UK, only one report coming from North America; this supports the concept that privational vitamin D deficiency is an important pathogenetic factor in the development of hepatic osteomalacia, as the availability of ultraviolet irradiation in the UK is considerably less than in North America. The most recent studies from the UK indicate that the prevalence of osteomalacia is falling,72 probably reflecting the changing clinical spectrum of primary biliary cirrhosis.126 Those patients most at risk appear to be jaundiced patients with chronic cholestatic liver disease; however, osteomalacia has also been reported in patients with alcoholic liver disease and chronic active hepatitis.11 13 10

In view of the low prevalence of osteomalacia in chronic liver disease, routine vitamin D prophylaxis seems unwarranted. Prophylaxis may however, be indicated in high risk patients with severe prolonged cholestasis, and reduced exposure to ultraviolet irradiation. For these patients and for those with documented osteomalacia, oral doses of between 400 and 4000 IU are probably adequate in most cases21; these doses are much less likely to be associated with hypercalcaemia than the high dose parenteral therapy which has traditionally been advocated.

The investigation of osteoporosis has been revolutionised over the past few years by the development of techniques which accurately measure bone mineral content in clinically relevant skeletal sites. No large study in patients with chronic liver disease has yet been reported using these techniques; however, because prevalence rates of around 30% have been reported for both cortical and trabecular osteoporosis using relatively insensitive diagnostic techniques, it seems likely that osteoporosis will emerge as a major complication of chronic liver disease. Vertebral crush fractures appear to be the most common clinical complication of osteoporosis associated with chronic liver disease and thus measurements of spinal trabecular bone mineral content will be of particular interest.

The pathogenesis of osteoporosis in patients with chronic liver disease has received little attention. Calcium malabsorption, vitamin D deficiency with secondary hyperparathyroidism, alcohol and corticosteroid therapy129 130 are all possible factors; in addition, oestrogen deficiency will contribute in peri- and postmenopausal women. The pathophysiological basis of the osteoporosis appears to be osteoblastic dysfunction rather than excessive bone resorption.

The prevention and treatment of osteoporosis in patients with chronic liver disease pose many problems, partly because these topics have been so little studied and partly because oestrogens, known to be effective in preventing postmenopausal bone loss, are contraindicated in many
patients with liver disease, as are anabolic steroids. Calcium supplementation reduces cortical bone loss in chronic cholestatic liver disease but its effect on vertebral trabecular bone or on cortical and trabecular bone loss in the femoral neck is unknown. Fluoride therapy has not been evaluated. With the increasing availability of techniques such as qualitative computerised tomography and dual photon absorptiometry accurate documentation of the effects of agents on bone loss in chronic liver disease has become a practical possibility and provides an important area for research in the future. The choice of therapy is difficult, but fluoride is a possible candidate and calcium supplements deserve further investigation. Oestrogen therapy should also be evaluated in suitable patients; hepatic toxicity may be reduced by the use of oestrogen implants or transdermal administration, although the effect of these preparations on spinal trabecular bone loss in the normal population has not been documented. Once effective therapies have been established, prophylaxis may well be indicated in high risk patient groups – for example, those with corticosteroid treated chronic active hepatitis and postmenopausal women with primary biliary cirrhosis.

J E COMPSTON

University of Wales College of Medicine, Dept of Pathology, Heath Park, Cardiff CF4 4XN

References

13 Long RG, Meinhard E, Skinner RK, Varghese Z, Wills MR, Sherlock S. Clinical,


33 Greaves JD, Schmidt CLA. The role played by bile in the absorption of vitamin D in the rat. J Biol Chem 1933; 102: 101–12.


Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease

62 Birkenhager-Frenkel DH, Schmitz PIM, Bruels PNWM, Lockefer JHM, Heul ROvD. Biological variation as compared to interobserver variation and intrinsic error of measurement for some parameters, within single bone biopsies. In: Meunier PJ, ed.


Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease


94 Wangensteen OH. Complete external biliary fistula. *JAMA* 1929; 93: 1199-204.


117 De Vernejoul MC, Bielakoff J, Herve M, *et al.* Evidence for defective osteoblastic


